Key Highlights

  • Dr. Mehmet Oz leads the Centers for Medicare & Medicaid Services.
  • He framed the rule as a way to crush fraud, waste and abuse.
  • The wording echoes the rule's acronym.
  • Insurer stocks fell for a second straight day.

Oz's framing

Dr. Mehmet Oz, the Administrator of the Centers for Medicare & Medicaid Services, has described the agency's latest proposal in pointed terms. He framed the rule as a way to "crush fraud, waste, and abuse."

The wording echoes the rule's own name. The proposal, released on Monday, November 16, is called "Comprehensive Regulations to Uncover Suspicious Healthcare," which forms the acronym CRUSH. Fraud, waste and abuse is a long-standing phrase in Washington for improper government spending, covering everything from deliberate deception to billing errors and inefficient payments.

What the rule would do

The proposal targets Medicare Advantage, the program through which private insurers such as UnitedHealth Group (NYSE:UNH), Humana (NYSE:HUM), Elevance Health (NYSE:ELV) and CVS Health (NYSE:CVS) provide Medicare coverage. CMS pays those plans more for members with more serious health conditions, based on the diagnoses the plans report.

The rule would let CMS extrapolate findings from its risk adjustment data validation audits, which review a sample of medical records, to an entire contract. It would also extend the audit and overpayment lookback to payment year 2018. CMS says the rule could save about $90 billion over 10 years.

The rule is not final. Public comments are due January 19, 2027.

Why the framing matters

How a regulator describes a rule can shape the public debate around it. Presenting the proposal as an anti-fraud measure casts it in terms of how taxpayer money is spent, and it puts the focus on the accuracy of the diagnoses that drive payments to plans.

The proposal also has a legal history. It revives a 2023 RADV rule that a federal judge in Texas vacated in September 2025 in a case brought by Humana. Oppenheimer expects legal challenges. One analyst said, "The substantially larger collection estimate reflects broader auditing," and noted that CMS "could choose to make adjustments in the final rule."

The political spotlight on insurers extends beyond CMS. Sen. Elizabeth Warren wrote on X that UnitedHealth, CVS and Cigna (NYSE:CI) "each own a health insurer, pharmacy middleman, and pharmacy" and "take a cut at every step."

Insurer stocks take the hit

Investors focused on the potential financial impact. Health insurer stocks fell for a second straight day on Wednesday. UnitedHealth tumbled and was the worst performer in the Dow Jones Industrial Average, and Humana plunged to finish as the worst performer in the S&P 500. Elevance, Centene (NYSE:CNC) and CVS also sank. Humana is particularly exposed, with Medicare Advantage accounting for $99.4 billion of its $129.7 billion in 2025 revenue.

The losses weighed on the broader market. The Dow fell 561.25 points to 50,198.17, with UnitedHealth the biggest drag. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss, and health care was among its weakest sectors.

How Oz's Framing Shapes the Insurer Debate

The comment period ending January 19, 2027, will give insurers, doctors, patient groups and others a formal chance to respond to CMS's proposal. Investors will watch whether the final rule keeps the extrapolation approach and the 2018 lookback, whether Oz and CMS add detail to the anti-fraud case, and whether any legal challenge is filed. UnitedHealth's 2027 outlook, expected before year-end, will show how the industry's largest player is weighing the proposal.